Real-world data show Novartis drug Promacta® improves outcomes for ITP patients compared to other second-line therapies

EAST HANOVER, N.J., Dec. 2, 2018 /PRNewswire/ -- Novartis announced results of a retrospective, real-world evidence study in patients with immune thrombocytopenia (ITP) treated with Promacta® (eltrombopag), compared to other second-line therapies. The data demonstrated that patients...

from PR Newswire: https://ift.tt/2DWnaTt